From neuroprogression to neuroprotection : implications for clinical care

Berk, Michael, Conus, Philippe, Kapczinski, Flávio, Andreazza, Ana C, Yücel, Murat, Wood, Stephen J, Pantelis, Christos, Malhi, Gin S, Dodd, Seetal, Bechdolf, Andreas, Amminger, G Paul, Hickie, Ian B and McGorry, Patrick D 2010, From neuroprogression to neuroprotection : implications for clinical care, Medical journal of australia, vol. 193, no. 4, pp. 36-40.

Attached Files
Name Description MIMEType Size Downloads

Title From neuroprogression to neuroprotection : implications for clinical care
Author(s) Berk, MichaelORCID iD for Berk, Michael
Conus, Philippe
Kapczinski, Flávio
Andreazza, Ana C
Yücel, Murat
Wood, Stephen J
Pantelis, Christos
Malhi, Gin S
Dodd, SeetalORCID iD for Dodd, Seetal
Bechdolf, Andreas
Amminger, G Paul
Hickie, Ian B
McGorry, Patrick D
Journal name Medical journal of australia
Volume number 193
Issue number 4
Start page 36
End page 40
Total pages 5
Publisher Australasian Medical Publishing Company
Place of publication Strawberry Hills, N.S.W.
Publication date 2010-08-16
ISSN 0025-729X
Summary • Bipolar disorder follows a staged trajectory in which persistence of illness is associated with a number of clinical features such as progressive shortening of the inter-episode interval and decreased probability of treatment response.

• This neuroprogressive clinical process is reflected by both progressive neuroanatomical changes and evidence of cognitive decline.

• The biochemical foundation of this process appears to incorporate changes in inflammatory cytokines, cortisone, neurotrophins and oxidative stress. There is a growing body of evidence to suggest that these markers may differ between the early and late stages of the disorder.

• The presence of a series of tangible targets raises the spectre of development of rational neuroprotective strategies, involving judicious use of current therapies and novel agents. Most of the currently used mood stabilisers share effects on oxidative stress and neurotrophins, while novel potentially neuroprotective agents are being developed. These developments need to be combined with service initiatives to maximise the opportunities for early diagnosis and intervention.
Language eng
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2010, Australasian Medical Publishing Company
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 66 times in TR Web of Science
Scopus Citation Count Cited 78 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 680 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Wed, 22 Jun 2011, 12:32:44 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact